News

Dr. Reddy’s Laboratories announces the launch of Resof Total in India

Dr. Reddy’s Laboratories Ltd announced today that it has launched the generic version of Sofosbuvir 400mg and Velpatasvir 100mg fixed-dose combination, indicated for the treatment of Chronic Hepatitis C, under a brand name Resof Total, in India.

Dr. Reddy’s Resof Total tablets are available in bottle count size of 28.

Reddy-Laboratories-announces-USFDA-approval

Resof Total is used for the treatment of adult patients with Chronic Hepatitis C Virus, Genotype 1,2,3,4,5 or 6 infection

– Without Cirrhosis or with compensated cirrhosis

– With decompensated cirrhosis for use in combination with Ribavirin

The Sofosbuvir 400mg and Velpatasvir 100mg fixed-dose combination is a generic version of Gilead’s brand Epclusa. Treatment with this combination achieves a cure rate of more than 90% in all genotypes of Hepatitis C virus (1,23,4, or 6). Achievement of higher cure rate with this combination in Hepatitis C genotype 3 addresses a significant unmet need, since infection with genotype 3 of Hepatitis C is upto 70% in Indian patients infected with Hepatitis C.

Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon0Pin on Pinterest0Tweet about this on Twitter0
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top